Brief: Brii Biosciences Says TSB Therapeutics Partnering With China Resources Pharmaceutical Commercial
19/07/2022 09:32
July 19 (Reuters) - Brii Biosciences Ltd 2137.HK :
* TSB THERAPEUTICS PARTNERING WITH CHINA RESOURCES
PHARMACEUTICAL
COMMERCIAL
* PARTIES WORKING TOGETHER TO ENSURE TIMELY DRUG SUPPLY TO
SUPPORT
COVID-19 PREVENTION & CONTROL EFFORTS IN CHINA
* PARTNERSHIP TO ADVANCE STOCKPILING AND HOSPITAL ACCESS FOR
CO'S
LONG-ACTING NEUTRALIZING MONOCLONAL ANTIBODY THERAPY
Source text for Eikon: ID:nHKS1lCVyN
Further company coverage: 2137.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR